Screen shots of the Viz Cardio Suite with the FDA-cleared AI module for pulmonary embolism (Viz PE) on the left and the company’s ECG Viewer on the right. Credit: Viz.ai / Business Wire.

Viz.ai has introduced a complete cardiology suite, called Viz Cardio Suite, to improve patient access to cardiovascular treatments.

The company’s Viz Platform is designed for identifying patients with specific cardiovascular diseases and aiding in the making of critical decisions at the point of care, which improves care pathways and outcomes.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It leverages artificial intelligence (AI)-powered workflow optimisation, disease detection and care team coordination to increase efficiencies in providing cardiovascular care.

The company stated that the new Viz Cardio Suite streamlines care pathways by enhancing the identification of patients, creating disease-specific workflows and linking patients with healthcare providers at each stage of their medical journey.

The suite features a mobile electrocardiogram (ECG) viewer that allows care teams to easily access and see all 12-lead ECGs flowing through the health system.         

The Cardio Suite also allows ECGs to be compared with earlier ones and includes a mobile and web cardiac imaging viewer.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Data from the platform can be shared through a HIPAA-compliant app.

The company uses Us2.ai’s software to produce complete AI-structured echo reports in less than two minutes.

Viz.ai CEO Chris Mansi said: “Viz.ai is fast becoming adopted across US health systems as the system of action. The comprehensive Viz Cardio Suite brings these capabilities to cardiovascular disease, where optimal patient outcomes often depend on the patient reaching the right therapy fast.

“Not only does the Viz Cardio Suite leverage AI to detect more disease in more patients, but it also accelerates the care pathway.

“This can improve quality of care for patients and working practices for cardiologists, while at the same time increasing hospital revenue and reducing overall healthcare costs.”

Last year, the company obtained CE mark for its AI-driven stroke care software, Viz LVO, in the European Economic Area.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact